Determing the cellular immunophenotype-genotype interactions in pancreatic cancer towards targeted personalized immunotherapies

Determing the cellular immunophenotype-genotype interactions in pancreatic cancer towards targeted personalized immunotherapies - Immunophenotype-genotype interactions in pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45339

Enrollment

Registered

2017-10-04

Start date

2017-11-09

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer Pancreatic Ductal AdenoCarcinoma

Interventions

Pancreatic cancer

Personalized immunotherapies

Immunophenotype

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Pancreatic cancer tissues and immune cells from patients diagnosed with severl types of pancreatic caner planned to undergo explorative surgery with or without resection.

Exclusion criteria

Exclusion criteria: Severe anemia (Hb

Design outcomes

Primary

Measure	Time frame
The main study endpoint consists in determining which immunophenotype-genotype interactions play a dominant role in the pathogenesis of PDAC and if we can therapeutically target these interactions. We will also be able to correlate the immunophenotyping with overall survival thereby conceptualizing an immunoprofile score.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)